Agenda for Day 2 - Tuesday 10 November, 2026Tuesday, 10 November 2026

Location: Biomanufacturing Strategy Stage

This engaging fireside chat will feature insights from industry leaders on the future of biopharmaceutical manufacturing, exploring transformative innovations, emerging technologies, and strategic approaches shaping the next generation of production capabilities. The discussion will cover:

• Designing scalable manufacturing processes that seamlessly transition from clinical to commercial production while maintaining product quality and regulatory compliance

• Innovations in biopharmaceutical manufacturing technologies driving efficiency and advancing production capabilities

• The role of automation and AI in streamlining production processes and enhancing operational decision-making

• Addressing regulatory challenges in manufacturing to ensure compliance while maintaining agility in an evolving landscape

• Sustainability in manufacturing processes as a critical component of responsible biopharmaceutical production

• Preparing for the next wave of biopharmaceutical advancements including novel modalities and breakthrough therapies

Location: Biomanufacturing Strategy Stage

As advanced therapies move closer to commercialization, companies face the challenge of aligning clinical development, manufacturing readiness, technology transfer, regulatory strategy, and market access planning. This presentation shares strategic lessons learned in preparing cell and gene therapy programs for launch and explores how integrated planning can accelerate patient access.

Location: Biomanufacturing Strategy Stage

Examine the unique economic and operational challenges of manufacturing cell and gene therapies, mRNA products, and other advanced modalities. Explore strategies to achieve commercial viability and patient access.

• Examining the unique economic challenges of manufacturing cell and gene therapies, mRNA products, and other advanced modalities

• Exploring cost-of-goods strategies to achieve commercial viability while maintaining product quality and patient access

• Addressing scalability and infrastructure requirements for transitioning from clinical to commercial-scale production

• Leveraging platform technologies and process innovations to drive manufacturing efficiency and reduce unit costs

• Navigating pricing, reimbursement, and market access challenges in the advanced therapy landscape

• A forward-looking perspective on sustainable manufacturing models and their potential to transform patient care globally

Location: Clinical Strategy Stage

• Examine cost-benefit frameworks for bridging studies across Japan, Korea, Taiwan and ASEAN countries, balancing regulatory requirements, ethnic sensitivity considerations and commercial ROI to accelerate regional approvals

• Explore the unique regulatory pathways and requirements across key Asian markets, including PMDA (Japan), MFDS (Korea), TFDA (Taiwan) and emerging frameworks in Southeast Asian nations

• Discuss proven strategies for managing multi-country trials in the region, including site selection and engagement in mature and emerging markets, patient recruitment in heterogeneous populations and building sustainable partnerships with local CROs and research institutions

• Future-Proof emerging opportunities across Southeast Asia's growing clinical trial ecosystem, the rise of decentralized and hybrid trial models adapted to Asian healthcare systems and how to leverage real-world evidence and digital health innovations tailored to local market needs

Location: Clinical Strategy Stage

• Address unique regulatory hurdles and innovative approval pathways for rare disease clinical trials, including adaptive designs and strategies for generating robust evidence with limited patient populations

• Examine the impact of political and leadership changes at the FDA and across global regulatory agencies, and how these shifts influence drug development priorities, review timelines, and enforcement approaches

• Align trial design with evolving regulatory requirements by incorporating real-world evidence, digital endpoints, and quality-by-design principles that strengthen submissions and accelerate approvals

Location: Clinical Strategy Stage

Australia offers a compelling opportunity for clinical trials, with favorable regulatory framework, strong networks, excellent engagement with clinicians/researchers, and access to established and proven pathways of obtaining high-quality clinical data recognised by European and US regulators, and other global institutions. This speaking session will highlight how Australia’s clinical trials are a cornerstone for innovation and attractive environment for companies from around the world to develop their intellectual property.

Location: Clinical Strategy Stage

• Learn best practices for strategic trial hub positioning globally, CRO selection, and building local partnerships to accelerate trial timelines while navigating the balance between market access and recruitment feasibility

• Address infrastructure and resource challenges in emerging markets by understanding the patient journey, establishing strong site relationships, and implementing effective strategies for working in diverse regions

• Discover actionable approaches for expanding trial footprints into underserved populations, including conducting proper due diligence and research to identify optimal locations for clinical trial success

Location: Clinical Strategy Stage

As Europe positions itself as a leading destination for clinical research, the ability to deliver clinical trials at scale requires robust operational frameworks and strategic site management. This fireside chat explores what it takes to transform Europe into a thriving clinical trials hub, examining the critical operational elements that enable successful trial execution across diverse European markets.

• Assess the regulatory, infrastructure, and market factors positioning Europe as an attractive hub for clinical research

• Learn how to evaluate site capabilities and optimize performance using data-driven approaches tailored to Europe's diverse healthcare systems

• Understand best practices for streamlining study initiation processes, managing cross-border logistics, and accelerating timelines

Location: Clinical Strategy Stage

• Discover how AI streamlines clinical trial operations- from intelligent protocol development and patient recruitment to digital twin technology that reduces patient requirements while maintaining regulatory compliance

• Learn strategies for shifting from traditional site-centric approaches to patient-focused trial designs that improve accessibility, diversity, and retention through decentralized and hybrid methodologies

• Explore real-world case studies and expert predictions on AI's future impact in precision medicine, regulatory evolution, and the transformation of clinical research operations

Location: Biomanufacturing Strategy Stage

This session highlights strategies and innovations to achieve excellence in biologics manufacturing. Key topics include:

• Addressing capacity constraints and exploring strategies for expansion

• Leveraging innovative technologies to enhance flexibility and efficiency

• Innovations driving advancements in biologics production processes

• Identifying and resolving bottlenecks in biologics manufacturing workflows

• Case studies showcasing successful biologics manufacturing practices

Location: Biomanufacturing Strategy Stage

• Selecting strategies for commercially viable, future-proof products through multi-regional scale-up

• Strategic timing and decision framework for manufacturing finalization at Phase II completion

• Navigating CMC requirements across FDA, EMA, and global regulatory jurisdictions

• Vendor based partnership - importance for business continuity and scaling

• Technology transfer and process validation strategies for commercial-scale production

• Capacity planning and manufacturing network design for global market launch

• Risk mitigation approaches for maintaining process flexibility while meeting regulatory expectations

• Real-world lessons learned from NEXTCELL PHARMA's journey to commercial readiness

Location: Biomanufacturing Strategy Stage

• what are the key considerations as you start developing your manufacturing process and setting up your network?

• to patent or not to patent? The role of trade secrets

• who are the potential partners going forward: a CDMO vs a collaboration partner

• IP due diligence readiness: demonstrating IP strength and FTO clarity

Location: Biomanufacturing Strategy Stage

The path to commercialization has become increasingly complex. While technical expertise, quality and speed remain essential, biopharma companies are now making manufacturing decisions against a backdrop of geopolitical uncertainty, shifting trade dynamics, regional market requirements and continued pressure on capital efficiency.

As a result, the criteria for selecting and managing manufacturing partners are evolving. Companies must balance resilience with flexibility, geographic diversification with operational efficiency, and short-term execution with long-term strategic value. At the same time, partnerships are becoming more strategic, requiring greater alignment, transparency, and shared accountability across the product lifecycle.

In this fireside chat, biopharma and industry leaders will discuss how outsourcing and manufacturing strategies are changing in response to today's realities. The conversation will explore how outsourcing priorities have evolved over the past three to five years, whether regionalization, friend-shoring and near-shoring are influencing partner selection, and how companies and manufacturing partners can best balance value, risk and reward to build resilient, long-term partnerships that support successful commercialization.

Location: Biomanufacturing Strategy Stage

• Importance of fostering collaborative ecosystems to drive innovation.

• Designing incentive structures like milestone-based models and risk-sharing agreements.

• Promoting open innovation while balancing intellectual property protection.

• Aligning stakeholders on shared goals through effective communication and trust-building.

• Leveraging advanced technologies like AI and automation to support innovation.

• Case studies showcasing successful partnerships that accelerated breakthrough therapies

Location: Biomanufacturing Strategy Stage

• China's Rise as a Global Manufacturing Powerhouse - How Chinese CDMOs are transforming from contract manufacturers to strategic innovation partners for Western pharma

• Bridging East-West Regulatory Frameworks - Aligning NMPA requirements with FDA/EMA standards for seamless global commercialization

• Diversification Without Disruption - Leveraging China's manufacturing scale while building geopolitical resilience into your supply chain

• Co-Innovation for Novel Modalities - Unlocking collaborative opportunities in cell and gene therapy development through Chinese partnerships

• Accessing China's Expanding Infrastructure - Strategic approaches to tap into China's growing biomanufacturing capacity for clinical and commercial production

• Future-Proofing Your Asia-Pacific Strategy - Building sustainable partnerships that balance IP protection, market access, and long-term growth in China's evolving landscape

Location: Biomanufacturing Strategy Stage

This talk focuses on innovation as a key driver of growth in the biopharmaceutical industry. It explores several interconnected dimensions:

• How innovation drives growth in biopharma
• Balancing innovation with scalability
• The role of emerging technologies in growth
• Case studies of innovative breakthroughs
• Future outlook for innovation in biopharma

Location: Industry Voices Stage

The EIC VentureMatch Pitching on Health Biotech spotlights 12 of the best health biotech companies backed by the European Innovation Council, working in therapeutics and advanced therapies, in technologies supporting research, development and clinical decision-making, and in adjacent health biotech fields. They have come through EIC evaluation, one of the most competitive selection processes in Europe, and hold EU grant funding, equity investment, or both. They will pitch to investors and pharma business development teams, followed by structured networking. If you would like to get involved or attend, please contact venturematch@bas.eic.eismea.eu.

AndzonBio2 is a VC-backed preclinical biotechnology company developing first-in-class small molecule therapies targeting neuroinflammation for neurological disorders.
Founded 2025 with a 3 M€ in seed funding from AdBio Partners and Inserm Transfert, the company is led by an international team with significant entrepreneurial / BD / scientific / drug development experience in neuroscience.
We develop therapeutics modulating neuroinflammatory pathways which are increasingly recognized as a pathological driver in multiple brain disorders. Our pipeline includes two complementary programs:
- a STING inhibitor, in-licensed from University of Cambridge (UK), currently in lead optimisation. The program has demonstrated promising PK properties, in vivo target engagement and a differentiation/superiority profile versus existing approaches.
- an ACSL4 inhibitor, developed in collaboration with Inserm Transfert and the University of Lille (France), currently in Hit-to-Lead optimization. The program targets ferroptosis, an emerging pathway increasingly recognized as a key contributor to neurodegeneration and neuroinflammation.
We are currently raising 15 M€ pre-Series A financing to advance the STING program to clinical candidate nomination and progress our ACSL4 inhibitor through late lead optimization. At the same time, we are actively seeking strategic partnerships with pharmaceutical companies and investors interested in differentiated neuroinflammation and CNS innovation.

Avecho Biotechnology Limited (ASX: AVE) is an Australian clinical-stage biopharmaceutical company that develops differentiated pharmaceutical products and advances them through clinical development to commercialisation and licensing. The company builds on a proprietary drug-delivery platform, TPM®, which enhances the solubility, absorption and tolerability of established compounds - enabling improved, differentiated products across human and animal health.

Avecho's lead program is a pivotal Phase III trial of a proprietary oral product for the treatment of chronic insomnia, one of the most prevalent and undertreated conditions worldwide. A positive interim analysis in 2026 supported the trial's continuation to full enrolment, and Australian commercial rights are already licensed to a global pharmaceutical partner. Avecho is now pursuing further licensing agreements internationally while progressing a broader pipeline of differentiated human and animal health products.

Headquartered in Melbourne, Avecho combines proven science, a partnered late-stage asset and a scalable, IP-protected platform to create and commercialise products that deliver more for patients, partners and shareholders.

Clinical stage precision psychiatry company.

Tiziana Life Sciences is focused on our main novel asset, foralumab, a fully human, anti-CD3 which is showing to reduce microglia activation in neuroinflammatory and neurodegenerative diseases through a simple nasal delivery device.

Foralumab, a fully human anti-CD3 is delivered intranasally where it binds to the T-cell receptor complex in the cervical lymph node. This creates and activates Tregs. These Tregs then cross the blood brain barrier and regulate the innate immune system (microglia). In our Multiple Sclerosis expanded access program we have shown to reduce microglia activation in PET scans and then onwards to show clinical improvement and also shown in an AD mouse model published in the PNAS. Emerging evidence suggests that dysregulation of neuroinflammation, particularly that orchestrated by microglia, plays a significant role in the pathogenesis of Alzheimer's disease (AD). Danger signals including dead neurons, dystrophic axons, phosphorylated tau, and amyloid plaques alter the functional phenotype of microglia from a homeostatic (M0) to a neurodegenerative or disease-associated phenotype, which in turn drives neuroinflammation and promotes disease. Thus, therapies that target microglia activation constitute a unique approach for treating AD. We will be presenting our Phase 2 na-SPMS data at Bio Europe.

BIORCHESTRA is a biotechnology company developing RNA therapeutics for central nervous system (CNS) diseases. Its proprietary BDDS™ platform is designed to enable systemic delivery of oligonucleotide therapeutics across the blood-brain barrier and into brain parenchyma following intravenous administration. BDDS™ uses multivalent L-phenylalanine ligand to engage the LAT1/CD98hc heterodimer and promote CNS uptake.
The platform has demonstrated in vivo proof of concept with two distinct miRNA-targeting oligonucleotide payloads that produce target protein up[BR1.1][IY1.2][YK1.3]regulation in the CNS, supporting the potential versatility of BDDS™ across therapeutic programs. All efficacy studies were conducted using intravenous dosing without intracerebral administration.
For BMD-002, in chronic epilepsy models, a single intravenous dose of a BDDS™-formulated miRNA-targeting oligonucleotide [YK2.1]increased GABRA1 protein 2.3-fold in the hippocampus at week 8, produced significant seizure protection from weeks 3 to 10, and maintained measurable target microRNA suppression at week 13. The findings were reproduced in two independent chronic seizure models, and combination treatment with standard anti-seizure medications achieved comparable protection at 2- to 3-fold lower medication doses.
For BMD-001, in a Parkinson's disease model, four weekly intravenous doses administered during months 1 and 2 produced effects that persisted through month 6, four months after the final dose. Motor performance was preserved across three behavioral tests, pathological α-synuclein was reduced in the substantia nigra, striatum, and cortex, dopaminergic neurons were preserved in the substantia nigra, and an astrocyte marker was reduced.
BIORCHESTRA is advancing BMD-002 for epilepsy and BMD-001 for neurodegenerative diseases while seeking global development, licensing, and strategic collaboration opportunities for its therapeutic assets and BDDS™ platform.

A-Alpha Bio is a biotechnology platform company that measures, predicts, and engineers protein-protein interactions at scale. Its experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously. Its AI platform, AlphaBind, is trained on the world's largest protein-protein interaction database and predicts binding strength from sequence. A-Alpha Bio works with pharmaceutical and biotechnology companies through both strategic partnerships and streamlined services, leveraging AlphaSeq and AlphaBind to engineer next-generation dual-specific and molecular glue therapeutics, discover and optimize differentiated biologics, and generate protein binding and structural data at scale to power AI models. A-Alpha Bio is based in Seattle and was founded in 2018 at the University of Washington's Institute for Protein Design.

AinB is an AI-native biotechnology company founded in 2022 in Seoul, Korea, dedicated to transforming antibody drug discovery. Its proprietary ALT:D (Antibody Less Than Days) platform is a closed-loop, sequence-based AI system that simultaneously optimizes efficacy, safety, and developability across the full antibody sequence - delivering wet-lab validated antibody candidates in 28 days, with hit rates exceeding 10%. Built by a founding team with deep combined expertise in antibody drug development and AI engineering. AinB connects Data, AI, and the Lab as a single closed loop, rather than pairing AI with experiments as separate steps. Every experiment AinB runs generates new data that retrains the model, and the model in turn keeps improving on its own.

Orvida Pharma is a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies for rare and underserved severe skin diseases. The company is focused on targeting the TRPV3 pathway, a validated ion-channel pathway involved in skin differentiation and barrier function, with the potential to address multiple orphan indications including Olmsted syndrome, Pachyonychia congenita, and ichthyosis.

Orvida's lead program, Ontivatrep (KM-023), is a highly specific oral TRPV3 inhibitor currently in clinical development. The program has successfully completed Phase 1a with no treatment-related adverse events, and a Phase 1b trial in patients with Olmsted syndrome was initiated in Q1 2026, with results expected in Q4 2026. Additional indications are planned to follow in 2027.

With no approved disease-modifying therapies currently available for these conditions, Orvida is advancing a focused, mechanism-driven development strategy aimed at restoring skin structure and function, reducing disease burden, and improving quality of life for patients with rare genetic skin diseases. The company's oral and topical TRPV3 programs, strong IP estate, Orphan Drug Designation, and a Pediatric Review Voucher support significant development and exclusivity potential.

Ewopharma AG, headquartered in Schaffhausen (Switzerland), is a pharmaceutical marketing company focused on Central Eastern Europe and Switzerland. With more than 60 years presence in the region, Ewopharma has extensive knowledge of these markets and enjoys a privileged position in the area. The company covers all aspects of market access and commercialisation of ethical pharmaceutical and consumer health products.

MitoRx Therapeutics is a preclinical stage biotech developing new treatments to restore healthy mitochondrial metabolism in patients living with high-risk obesity.

Our first-in-class small molecule asset, MTRX31, targets the elimination of ectopic fat from affected organs in people with metabolically unhealthy obesity, by restoring mitochondrial health rather than suppressing appetite.

Metabolic inflexibility in obesity completes a vicious cycle of lipotoxicity in which impaired carbohydrate utilization feeds into de novo lipogenesis (Kelley and Mandarino 2000). Our approach breaks this cycle and restores the metabolic state to that of a lean individual without a net reduction food intake nor any requirement for exercise, better reflecting patients' ability to modify behaviour.

In data released at ADA 2026, MTRX31 has demonstrated superiority over tirzepatide in quantity, durability and quality of weight loss in the industry standard thermoneutral rodent DIO model run over 56 days, with MTRX31 monotherapy driving 62% reduction in fat percentage vs. DIO vehicle. MTRX31 was associated with zero loss of lean mass. Superior clearance of fat from pancreas and liver was also achieved alongside restoration of insulin sensitivity. An improvement in circulating lipid profile was achieved suggesting improved cardiovascular health. Synergy with twincretin (tirzepatide) achieved 77% reduction in fat percentage vs. 40% with tirzepatide alone.

This approach has the potential to deliver durable and higher quality weight loss, lower the risk of cardiovascular complications and other serious diseases, and improve quality of life.

MitoRx has a lead program MTRX31 (sc) in obesity and is progressing an oral follower program driven by its Candidate Engine discovery platform.

MitoRx is interested in speaking to investors about participation in our next financing. The full target ID package, mode of action, ADME/PK, DIO data & asset profile are available in VDR under CDA.

PostEra is building an AI-first biotech. We use Proton, our AI platform for medicinal chemistry, to accelerate the discovery of new medicines for patients. PostEra is advancing an internal pipeline focussed on Women's Health and Fertility, and has used Proton to nominate multiple clinical candidates across PMOS (indication formerly known as PCOS) and Fertility. PostEra also advances small molecule programs through partnerships with pharma. We've closed over $1B in AI partnerships including 4 multi-year agreements with Pfizer and Amgen, working across a wide spectrum of indications. PostEra is also leading an antiviral drug discovery center for pandemic preparedness, funded by one of the largest grants in NIH history.

Variant: Redefining the Treatment of Inherited Retinal Dystrophies

At Variant, we are developing breakthrough treatments to address the unmet medical needs of patients living with rare genetic vision disorders. Inherited retinal dystrophies (IRDs) are caused by mutations in over 380 different genes, making individualized, gene-specific therapies costly, slow to develop, and commercially unsustainable for most patients. Variant takes a fundamentally different approach.
Our lead candidate, VAR-002, is a single, versatile gene therapy capable of treating multiple IRDs regardless of the mutated gene or disease mechanism. Rather than targeting an individual defective gene, VAR002 expresses the CRX transcription factor, a master regulator essential for the development and maintenance of photoreceptors in both cones and rods. VAR002 acts on two complementary levels: restoring proper photoreceptor identity where differentiation is impaired and delivering widespread neuroprotection where mature photoreceptors are degenerating. Through this dual mechanism, VAR002 restores meaningful visual function and slows disease progression across a broad range of retinal dystrophies.
This mutation-agnostic strategy allows Variant to address the genetic diversity of IRDs with one candidate, cutting development costs, shortening timelines, and expanding the number of treatable patients.
VAR002 combines innovation with reliability, built on a clinically validated AAV backbone and delivered via a proven administration route.
With a large addressable market, a de-risked path to the clinic, and a solid financial roadmap, Variant is well positioned to bring this therapy to patients with no other options, benefiting from regulatory advantages tied to rare disease designations, including expedited review and extended market exclusivity.

Artelo Biosciences is a clinical stage company using cutting-edge science to improve patient care. We were founded on the promise of therapeutic development based on lipid-signalling modification. Our mission is to alter the course of treatment for those with a diagnosis of cancer and other serious conditions.

Artelo's innovative approach targets acute and chronic conditions, including pain, cancer, anxiety, depression and other conditions through modulating lipid- signaling pathways. Emerging science suggests that modulating lipid-signaling pathways can unlock novel therapeutic strategies for diseases and medical conditions for which there are no or limited options.

Lipid-signaling modulation is the alteration of the signaling of lipid molecules to change biological activity or function within cellular communication pathways. Lipids contain various fatty acids as their building blocks and are the key components of lipid activity. Fatty Acid Binding Proteins (FABPs) facilitate lipid-signaling by binding to fatty acids which control various cellular functions. FABPs are essential mediators of normal cell signaling processes and under certain conditions can be associated with dysfunctional signaling. Inhibition of specific FABPs may correct abnormal lipid-signaling which holds promise as new
treatment modalities.

ART26.12, Artelo's lead Fatty Acid Binding Protein 5 (FABP5) inhibitor, is a potent and selective inhibitor of FABP5 being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic, with initial clinical development planned for chemotherapy-induced peripheral neuropathy. ART26.12 has successfully completed a single ascending dose study and Artelo will conduct a multiple ascending dose study in 2H 2026.

TLC BioSciences is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics using proprietary lipid-based drug delivery technologies. The company has extensive expertise in formulation development, clinical development, regulatory strategy, manufacturing, and global business development, with a track record of advancing novel products from research through commercialization and strategic partnering.

Since its founding, TLC has focused on addressing significant unmet medical needs by improving the efficacy, durability, safety, and convenience of existing therapeutics. Its proprietary platform technologies are designed to optimize drug delivery and create differentiated products with meaningful clinical and commercial advantages. TLC has established capabilities across multiple therapeutic areas, including pain management, metabolic diseases, infectious diseases, and advanced therapeutics.

Today, TLC's primary business development focus is on its pain management portfolio, where the company is advancing innovative long-acting therapies intended to improve patient outcomes while reducing treatment burden. With growing demand for non-opioid pain solutions and durable treatments for chronic musculoskeletal disorders, TLC is positioned to address large and underserved markets through differentiated products that leverage its proprietary technology platforms.

In addition to pain management, TLC continues to expand its pipeline into chronic metabolic diseases and next-generation cell and gene therapies. The company is actively pursuing strategic partnerships, regional licensing opportunities, and co-development collaborations to accelerate the global development and commercialization of its programs. TLC is headquartered in Taiwan and listed on the Taipei Exchange, with experience establishing partnerships across North America, Europe, Asia, and Latin America.

Azitra, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and novel products across therapeutics, cosmeceuticals and biotechnology applications. The Company's portfolio is highlighted by ATR-COSF, a recombinant protein technology designed for cosmetic and skincare applications, and ATR-04, an investigational live biotherapeutic for EGFR inhibitor ("EGFRi") associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra is also advancing additional recombinant protein initiatives designed to support biotechnology research and manufacturing applications. Azitra's technology platforms combine engineered proteins, topical live biotherapeutics, artificial intelligence, and a proprietary microbial library to develop differentiated products for consumer, research and healthcare markets. For more information, please visit https://azitrainc.com.

Avenue Biosciences is a transatlantic biotechnology company applying a unique combination of proprietary protein engineering with artificial intelligence and machine learning to one of the most overlooked challenges in biologics manufacturing: how therapeutic proteins are produced and secreted by living cells. Founded at the intersection of synthetic biology, high-throughput experimentation, and AI, Avenue has built a proprietary technology platform and one of the field's most extensive datasets connecting protein engineering choices to real-world expression outcomes in mammalian cell systems.
This data asset - generated through millions of experimental combinations and continuously expanded through the company's wet-lab and computational pipeline - gives Avenue's machine learning models a uniquely rich foundation for predicting and optimizing how proteins are produced, something few, if any, companies in the space can replicate. As biologics grow more structurally complex, from bispecific and multispecific antibodies to novel modalities in cell and gene therapy, this predictive capability becomes increasingly valuable and increasingly difficult for competitors to catch up to.
Avenue partners with biologics developers, CDMOs, and technology innovators to help bring higher-yielding, higher-quality, and faster-to-develop therapeutics to patients. Backed by seed financing and a growing base of commercial collaborations, Avenue is building the AI-driven infrastructure the biologics industry will depend on as the next generation of complex therapeutics moves from discovery to manufacturing at scale.

Infinite d.o.o. is a young deep-tech biotech company from Maribor (Slovenia), developing integrated and fully automated in-vitro-learned digital twin InFiniteDT solutions to rapidly assess long-term / chronic health hazard supporting advanced therapeutics optimization pipelines merging wet lab biology, automated cellular response monitoring, and autonomous Mode-of-Action discoveries. The first InFiniteLungDT digital twins are now being expanded with entire family of digital twins enable unprecedented cross-organ MoA-rescue use with identification of various on/off targets.

Kantify is a Belgium-based biotech using AI to discover new medicines against previously undruggable targets in oncology, CNS, and rare disease. Founded following a rare cancer diagnosis, the company was built on the conviction that patients with intractable diseases deserve access to molecules that conventional methods cannot reach.

Kantify's platform, Sapian, is an AI-native, orthogonal approach to drug discovery. It integrates target identification with non-structure-based small molecule discvery- pioneering a method that operates independently of traditional screening infrastructures. Sapian screens billions of compounds in silico, combining advanced multi-parameter optimization with proteome-wide safety prediction to deliver IP-free, selective preclinical candidates selected for reduced off-target risk.

The platform has been validated multiple times in vivo and through partnerships with leading biopharma and key opinion leaders in oncology and rare disease. Kantify has delivered first-in-class modulators for targets considered intractable by conventional methods, at a fraction of the typical timeline and cost, and is trusted by large biopharma to tackle some of the hardest problems in drug discovery.
Backed by Innoviris and the European Commission - and collaborating with Johns Hopkins, INSERM, CNRS, Leiden University, IBMCP and partners across Europe, the US and Asia.

Operating as a frontier lab with independent, sovereign technology, Kantify combines computational biology, medicinal chemistry, and machine learning to build a pipeline of novel therapeutics where patient need and technical difficulty intersect.

Pavonis Diagnostics Inc. is a Canadian biotechnology company developing VICA™, a proprietary thin-film optical biosensing platform designed to simplify and accelerate protein characterization, therapeutic discovery, and biomarker development. Unlike conventional technologies that often require separate instruments for binding analysis, immunoassays, and protein capture, VICA enables molecular binding measurements in both solution and solid-phase formats on a single platform while using low sample and reagent volumes. The technology supports sequential workflows including binding, specificity, conditional and pH-dependent interactions, competitor-displacement, off-rate analysis, capture, and elution, providing researchers with richer datasets from a single experiment. Protected by an issued U.S. patent and international patent filings, VICA is being developed for applications spanning antibody and peptide engineering, companion diagnostics, point-of-care testing, and veterinary diagnostics. By combining broad analytical capability with a portable, cost-effective platform, our team at Pavonis aims to expand access to high-quality protein characterization beyond specialized laboratories, enabling academic researchers, biotechnology companies, and diagnostic developers to accelerate discovery while reducing cost and experimental complexity.

Constellate Proteomics enables antibody therapeutic developers to assess the quality of their product as early and often as necessary, with a highly sensitive and versatile analysis platform. Their innovative single-molecule analysis technology allows Constellate devices to automatically analyze a variety of attributes - including titer, glycosylation properties, aggregation and charge variants. This data can be used to efficiently steer drug development processes from day 1, and build sophisticated digital twin models of antibody cell lines.

Studia is an AI medical writing platform built for clinical and regulatory documentation. It gives medical writers, clinical teams, sponsors, and CROs a purpose-built writing environment that connects regulatory guidance, clinical-study data, literature, internal knowledge, and AI-assisted drafting in one workspace.

Rather than using generic documents and disconnected tools, Studia helps teams draft, review, check, collaborate on, and export clinical documents with greater speed, consistency, and traceability. The platform is designed for documents such as clinical study protocols, clinical investigation plans, informed consent forms, investigator brochures, and related study documentation.

Studia supports the full writing workflow: a familiar editor, structured templates, source-connected content generation, automated consistency and quality checks, version history, real-time collaboration, and Word/PDF export. Its AI-assisted drafting is grounded in user-provided sources and public clinical/regulatory references, helping teams accelerate first drafts while keeping expert review and approval in human hands.

The company’s mission is to reduce friction in clinical development documentation so life-science teams can get high-quality study documentation right from the start, avoid late-stage rework, and bring therapies and medical technologies to patients faster.

RNATICS develops targeted nucleic acid therapies to selectively silence disease-causing RNAs in fibrotic lung diseases. Its proprietary targeting technology enables efficient and specific delivery of nucleic acid therapeutics to pulmonary macrophages via a receptor-ligand interaction following inhalation. The team pairs deep, long-standing RNA biology expertise with proven clinical and pharmaceutical development know-how, covering the path from discovery to patient. RNATICS’ lead candidate, RCS-21, is designed to target macrophage-driven fibrosis, by combining an antisense oligonucleotide against microRNA-21 with a proprietary macrophage-targeting moiety. Proof-of-concept studies in human lung tissue and preclinical models demonstrate that targeting microRNA-21 in pulmonary macrophages holds therapeutic promise for fibrotic lung diseases, providing a compelling rationale for developing RCS-21 as a targeted inhibitor. RCS-21 is currently in a first-in-human Phase 1 trial in healthy volunteers, with database lock for the single-ascending-dose phase approaching. The resulting data will provide the first clinical evidence for macrophage-targeted RNA therapy, evaluating its safety, tolerability, and initial evidence of target engagement. With RCS-21 advancing through Phase I, RNATICS is establishing a therapeutic approach to directly address disease-driving lung macrophages and unlock the potential of targeted RNA therapeutics for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF).

Clinmark is an experienced, full-service Contract Research Organization (CRO) supporting pharmaceutical, biotechnology, and medical device companies. Since 2001 we have successfully delivered over 450 research and consulting projects across 75+ countries. We are proud to have earned the trust of clients of all sizes – including several of the world’s top 10 pharmaceutical companies - by consistently delivering tailored, cost-effective, and high-quality solutions. With 25,000+ subjects enrolled globally and deep expertise across Central and Eastern Europe, we combine local knowledge with global oversight to ensure smooth, compliant, and efficient study execution.

iPark Institute is a leading life science innovation ecosystem builder in Japan, connecting pharmaceutical companies, biotech startups, academia, investors and other innovators to accelerate drug discovery and open innovation.

Building on our deep engagement with Japan’s life science ecosystem, we are developing iDCP, an Asia-Pacific DeepTech data and partnering platform designed to make promising innovation across the region more visible, accessible and actionable.

While a growing number of platforms provide company and technology intelligence, identifying high-potential opportunities from Asia-Pacific—particularly emerging academic research and early-stage innovation—remains challenging. Data coverage, quality and reliability can also vary significantly when information is collected and interpreted primarily through automated approaches.

iDCP addresses this gap by combining technology with ecosystem-driven, curated intelligence. The platform covers startups, academia and other DeepTech innovators, with an initial focus on drug discovery and the life sciences.

Users can register with an email address to access the platform and discover innovation opportunities across Asia-Pacific. iDCP also provides matching capabilities designed to connect registered organizations and facilitate partnerships between pharmaceutical companies, corporates and VCs on one side, and startups and academic innovators on the other.

For European pharmaceutical companies, investors and innovation teams seeking new opportunities in Asia, iDCP provides a gateway to discover and connect with emerging innovation that may otherwise be difficult to identify.

Our ambition is to create a trusted digital bridge between Asia-Pacific innovation and the global life science ecosystem.

eversyn is turning glycosylation — the sugar chains that shape a biologic's safety and efficacy — into a controllable design parameter. We precisely tune a biologic's half-life and immune effector function, without re-engineering the host cell line.

AB Cube is a software group that builds compliant technology for clinical research and drug safety. Its two product lines cover the path from trial data to safety reporting. Marvin, developed by AB-Cube Germany GmbH in Munich, is a modern, CDISC-ODM-certified eClinical platform with EDC/eCRF, IWRS/RTSM, medical coding (MedDRA, WHODrug), ePRO and SDTM-ready reporting. SafetyEasy®, developed by AB Cube in France since 2006, is a cloud-based multivigilance suite for case intake, ICSR processing, E2B(R3) regulatory reporting, aggregate reports and signal detection.

Together, Marvin EDC and SafetyEasy® work as one harmonized ecosystem. Safety cases are created directly from adverse event entries in the EDC, and SAE reconciliation between the clinical and safety databases runs automatically with a full audit trail. Sponsors and CROs replace manual spreadsheet comparisons and query loops with continuous, documented alignment that supports inspection readiness under GVP and ICH E6(R3).

AB Cube serves biotech companies, pharmaceutical sponsors, CROs, medical device manufacturers, academic institutions and health authorities. Marvin has supported more than 1,500 studies in 69 countries with over 2 million subjects enrolled.